Ottavio Arancio, PhD

Columbia University Medical Center
TAUB Institute
New York, NY
USA Papers:
37 Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma